- Home
- INVE vs EQ Comparison
INVE vs EQ Comparison
Compare INVE & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | EQ |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 129.0M |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | INVE | EQ |
|---|---|---|
| Price | $4.62 | $2.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.50 | ★ $8.00 |
| AVG Volume (30 Days) | 272.1K | ★ 400.2K |
| Earning Date | 05-07-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $60,219,000.00 | $41,095,000.00 |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $20.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $3.08 | $0.29 |
| 52 Week High | $4.84 | $2.70 |
Technical Indicators
Market Signals| Indicator | INVE | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 76.30 | 50.45 |
| Support Level | $3.25 | $1.60 |
| Resistance Level | N/A | $2.13 |
| Average True Range (ATR) | 0.22 | 0.21 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 83.80 | 40.88 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.